Paolo Tarantino: Focusing on HR+/HER2- Breast Cancer
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“HR+/HER2- is the most common MBC subtype and the one with the highest number of recent drug approvals. At SABCS24, I’ll have the honor of moderating a Medscape symposium focused on this subtype with Drs. Juric and Chavez MacGregor. Join us in person or virtually!”
More posts featuring Paolo Tarantino.
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023